BRPF1-Related Intellectual Disability (IDDDFP) — Comprehensive Research Report

Prepared: 2026-07-31 | Target for KB entry: BRPF1-Related_Intellectual_Disability

Verification note for curators: Every abstract quote below was transcribed verbatim from the NCBI E-utilities efetch output for the stated PMID. Every HPO/MONDO/GO/UBERON identifier suggested was checked against the HPO API (ontology.jax.org), OLS4, or UniProt. Where a claim could not be sourced to a citable abstract, it is explicitly flagged as [not verifiable / gap] rather than given a citation. Per the DR guardrails in CLAUDE.md, treat this document as leads: re-run just fetch-reference PMID:X and just validate-references before committing any snippet.

1. Disease Information

1.1 Overview

BRPF1-Related Intellectual Disability — formally Intellectual Developmental Disorder with Dysmorphic Facies and Ptosis (IDDDFP) — is a rare autosomal dominant neurodevelopmental syndrome caused by heterozygous loss-of-function variants in BRPF1, a multivalent chromatin-reader/scaffold protein that assembles and activates the KAT6A/KAT6B (MOZ/MORF) lysine acetyltransferase complexes. The disorder is a chromatinopathy: haploinsufficiency reduces histone H3 lysine-23 (H3K23) acetylation and propionylation, deregulating developmental transcriptional programs.

The core clinical triad is developmental delay / mild-to-moderate intellectual disability + prominent speech and language impairment + ptosis/blepharophimosis with characteristic facial dysmorphism. Relative to other monogenic chromatin-related neurodevelopmental disorders, cognition and adaptive behavior are comparatively preserved, while speech/language involvement is near-universal.

Yan et al. (2017) established the disorder (PMID:27939640):

"Here, we describe an intellectual disability disorder in ten individuals with inherited or de novo monoallelic BRPF1 mutations. Symptoms include infantile hypotonia, global developmental delay, intellectual disability, expressive language impairment, and facial dysmorphisms. Central nervous system and spinal abnormalities are also seen in some individuals."

"These data indicate that aberrations in the chromatin regulator gene BRPF1 cause histone H3 acetylation deficiency and a previously unrecognized intellectual disability syndrome." — PMID:27939640

1.2 Key identifiers

MONDO cross-reference set retrieved from OLS4 (MONDO:0015022 → OMIM:617333, Orphanet:698090, UMLS:C4310617, MedGen:934584). Orphanet identity confirmed via api.orphadata.com/rd-cross-referencing/orphacodes/698090, which reports disorder type "Malformation syndrome" and an exact, validated OMIM:617333 mapping.

1.3 Synonyms and alternative names

• Intellectual Developmental Disorder with Dysmorphic Facies and Ptosis (IDDDFP) — OMIM/MONDO preferred
• BRPF1-related neurodevelopmental disorder — Orphanet synonym
• Ophthalmological abnormalities–facial dysmorphism–intellectual disability syndrome — Orphanet preferred term
• BRPF1-related disorder / BRPF1-associated syndrome — literature usage (PMID:38346666; PMID:35243762)
• BRPF1 haploinsufficiency syndrome

⚠️ NEC (Named Entity Confusion) preflight note. BRPF1 sits in a family of closely related chromatin disorders with overlapping names — KAT6A syndrome (MONDO distinct), KAT6B-related Genitopatellar and Say-Barber-Biesecker-Young-Simpson syndromes, and the 3p25.3 microdeletion syndrome (which spans both BRPF1 and SETD5). It also phenocopies Noonan syndrome (PMID:41137536) and blepharophimosis-ptosis-epicanthus-inversus syndrome (FOXL2). Before accepting any deep-research report on this disease, confirm the report's dominant gene is BRPF1, and that the OMIM ID is 617333 (not 601358/KAT6A, 603736/KAT6B, or 110100/BPES). Run uv run runoak -i sqlite:obo:mondo info MONDO:0015022 -O obo.

1.4 Information provenance

Disease-level (aggregated) resources — OMIM, Orphanet, MONDO, ClinGen, HPO annotations — plus individual-patient case series and cohorts. There is no EHR-derived or registry-derived cohort for this disorder. The largest single patient-level source is Colson et al. 2025 (PMID:39837771, 29 new patients from 20 families + literature review). Deep-phenotyping sources: PMID:38346666 (15 participants, speech/language) and PMID:38590032 (ophthalmic OCT deep phenotyping).

2. Etiology

2.1 Disease causal factors

Genetic, monogenic, autosomal dominant. The sole established cause is heterozygous loss-of-function of BRPF1. The mechanism is haploinsufficiency — not gain of function or dominant negative — established by three converging lines of evidence:

1. Variant spectrum: the overwhelming majority of pathogenic variants are protein-truncating (nonsense, frameshift, canonical splice) plus whole-gene deletions (PMID:39837771).
2. ClinGen Dosage Sensitivity curation: haploinsufficiency score 3 (Sufficient Evidence for Haploinsufficiency); triplosensitivity score 0 (No Evidence); curated 2023-08-23 against MONDO:0015022 / OMIM:617333 (CGDS:HGNC_14255, ClinGen curation CCID:006763). ClinGen's summary: "Numerous loss-of-function mutations have been reported in intellectual developmental disorder with dysmorphic facies and ptosis (IDDDFP) patients, and functional analyses support a haploinsufficiency of the BRPF1 gene."
3. Functional assays: patient variants impair H3K23 acetylation (PMID:27939640) and H3K23 propionylation (PMID:32010779), and Brpf1 heterozygous mice recapitulate the cognitive phenotype (PMID:31213987).

ClinGen also records a Gene-Disease Validity classification for BRPF1; GenCC aggregates it as Definitive/Strong.

2.2 Risk factors

Genetic risk factors (causal): - De novo heterozygous BRPF1 LoF variants — the majority of cases. - Inherited variants from a mildly affected parent — well documented; five of 20 families in the 2025 cohort showed two-generation transmission (PMID:39837771). Multiplex families are reported: a 5-member family with c.1052_1053del (PMID:27939639) and a 4-member family with c.556C>T p.Q186 (PMID:31020800). - Contiguous 3p25.3 deletions encompassing BRPF1 (± SETD5*) — see §4.6.

Environmental risk factors: None identified. This is a fully penetrant-mechanism Mendelian chromatinopathy with no reported environmental, occupational, toxin, infectious, dietary, parental-age, or lifestyle risk contribution. Advanced paternal age is a generic risk factor for de novo point mutations across all dominant disorders, but has not been specifically studied in BRPF1 [gap].

Sex: Male predominance is observed in reported series (e.g. 10/15 male in PMID:38346666), but this is likely ascertainment bias, not a biological sex effect. No sex-linked mechanism exists (autosomal gene) [interpretive; not directly asserted in any abstract].

2.3 Protective factors

No genetic or environmental protective factors are established. Notably, however, there is documented variable expressivity extending to normal cognition — PMID:35243762 reports "a patient with normal intellectual development who had congenital ptosis, hypotonia, muscular weakness, atlanto-axial malformation, and pyramidal at the neurological examination," carrying "a rare nonsense variant on exon 3 of BRPF1 gene." The genetic or environmental modifiers underlying this preservation are unknown [gap — high-value research question].

A therapeutic (not protective-in-the-epidemiologic-sense) lead exists: short-chain fatty acids and HDAC inhibitors boost the deficient mark — see §12.

2.4 Gene–environment interactions

None described. No GxE studies exist for BRPF1. A mechanistically plausible but entirely untested hypothesis is that dietary short-chain fatty acid (propionate/butyrate) availability could modulate residual H3K23 acylation, given PMID:32010779's finding that "Valproate, vorinostat, propionate and butyrate promote H3K23 acylation." [hypothesis only — no human or animal GxE data]

3. Phenotypes

3.1 Frequency table — the primary evidence base

The best frequency source is Colson et al. 2025 (PMID:39837771), which reports 29 new patients (20 families) and a literature comparison cohort (~50 previously published cases). Frequencies differ substantially between the two — the newer prospectively phenotyped cohort shows lower rates of ID, speech delay, motor delay, microcephaly, short stature, and feeding difficulty, consistent with ascertainment bias in earlier case reports toward more severely affected individuals. Curators should record both and prefer the combined view.

HPOA-only features (from ontology.jax.org/api/network/annotation/OMIM:617333, derived from the original OMIM curation, not in the 2025 cohort):

3.2 Speech and language — the most consistent domain

PMID:38346666 provides the only systematic speech/language characterization (15 participants, median age 7y4m, 14 distinct variants):

"Language disorders were common (11/12), and most had mild to moderate deficits across receptive, expressive, written, and social-pragmatic domains. Speech disorders were frequent (7/9), including phonological delay (6/9) and disorder (3/9), and childhood apraxia of speech (3/9). All those tested for cognitive abilities had a FSIQ ≥70 (4/4). Participants had vision impairment (13/15), fine (8/15) and gross motor delay (10/15) which often resolved in later childhood, infant feeding impairment (8/15), and infant hypotonia (9/15)."

"We have implicated BRPF1-related disorder as causative for speech and language disorder, including childhood apraxia of speech. Adaptive behavior and cognition were strengths when compared to other monogenic neurodevelopmental chromatin-related disorders. The universal involvement of speech and language impairment is noteable, relative to the high degree of phenotypic variability in BRPF1-related disorder." — PMID:38346666

Suggested HPO terms: HP:0000750 Delayed speech and language development; HP:0011098 Speech apraxia (childhood apraxia of speech; verified label is "Speech apraxia"); HP:0002465 Poor speech.

Two curation-relevant nuances from this paper: - Vision impairment 13/15 (87%) — the highest ocular frequency in any series. - Motor delay is often transient ("which often resolved in later childhood") — argues for clinical_course annotation rather than PROGRESSIVE.

3.3 Ophthalmological phenotype — the syndrome's signature

Ocular involvement is the defining feature and is why Orphanet names the syndrome "Ophthalmological abnormalities–facial dysmorphism–intellectual disability syndrome." Mattioli et al. established that this arm is specifically BRPF1-driven within the 3p25 contiguous deletion:

"We conclude that both genes contribute to the phenotypic severity of 3p25 deletion syndrome but that some specific features, such as ptosis and blepharophimosis, are mostly driven by BRPF1 haploinsufficiency." — PMID:27939639

An important 2024 expansion added subclinical optic neuropathy, detectable only on OCT (PMID:38590032):

"Interestingly, P1 had a Chiari Malformation type I and a subclinical optic neuropathy, which could not be explained by variations in other genes. Having detected a peculiar ocular phenotype in P1, we suggested optical coherence tomography (OCT) for P2; such an exam also detected bilateral subclinical optic neuropathy in this case. To date, only a few patients with BRPF1 variants have been described, and none were reported to have optic neuropathy. Since subclinical optic nerve alterations can go easily undetected, our experience highlights the importance of a more detailed ophthalmologic evaluation in patients with BRPF1 variant."

Additional HPO terms: HP:0001098 Abnormal fundus morphology / HP:0000648 Optic atrophy (for optic neuropathy — no exact "subclinical optic neuropathy" term exists; use a more specific preferred_term per the dismech convention); HP:0007099 Chiari type I malformation.

3.4 Phenotype characteristics (onset, severity, progression)

• Age of onset: Congenital / neonatal — HPOA records HP:0003577 Congenital onset 10/10 and HP:0003623 Neonatal onset 4/4. Ptosis is congenital (PMID:35243762). Hypotonia and feeding difficulty present in infancy (PMID:38346666).
• Severity: Predominantly mild to moderate. PMID:39837771: "Neuropsychological assessment reveals a predominance of mild to moderate ID, with cognitive profiles showing variability in verbal and visual processing." In the 2025 cohort, of 16 with ID, 6 were mild and 10 moderate — no severe/profound ID reported. PMID:38346666: FSIQ ≥70 in all 4 formally tested.
• Progression: Non-progressive / static. This is a developmental (neurodevelopmental) disorder, not a neurodegenerative one. Motor delay frequently improves ("often resolved in later childhood," PMID:38346666). No abstract reports regression or neurodegeneration. Curate as clinical_course: STABLE for the neurological phenotype, not PROGRESSIVE.
• Variable expressivity: Marked, including intrafamilial. PMID:39837771: "Among the five families reported here, phenotypic differences were observed between family members carrying the same pathogenic variant, affecting intellectual ability, dysmorphic features and malformations, suggesting an intrafamilial variability." At the extreme, PMID:35243762 reports normal intellect with isolated congenital ptosis and neurological signs.

3.5 Quality of life impact

No disease-specific QoL instrument, EQ-5D, SF-36, or PROMIS data exist for BRPF1-related disorder [gap]. Per-phenotype functional impact can be inferred:

• Speech/language disorder + childhood apraxia of speech — the dominant functional burden; drives communication, literacy ("written" domain affected), and social-pragmatic participation (PMID:38346666).
• Ptosis/blepharophimosis — visual-axis obstruction risk, amblyopia (3/29), plus cosmetic/psychosocial impact; surgically correctable.
• Vision impairment (13/15) — affects learning and mobility.
• Behavioral phenotype (62% any; ADHD 33%, anxiety 21%, sleep disturbance 31%) — significant caregiver burden.
• Adaptive behavior is a relative strength — PMID:38346666: "Adaptive behavior and cognition were strengths when compared to other monogenic neurodevelopmental chromatin-related disorders." This is an important positive prognostic message.

4. Genetic / Molecular Information

4.1 Causal gene

BRPF1 (bromodomain and PHD finger containing 1), hgnc:14255, 3p25.3, OMIM 602410, Ensembl ENSG00000156983, NCBI Gene 7862. Protein: Peregrin, UniProt P55201, 1,214 aa, ~137.5 kDa. Clinical transcript commonly NM_004634.3; also NM_001003694 (RefSeq Select). Note the literature also uses ENST00000383829.

Domain architecture (UniProt P55201, verified):

PMID:27939640 describes this as "a multivalent chromatin regulator possessing three histone-binding domains, one non-specific DNA-binding module, and several motifs for interacting with and activating three lysine acetyltransferases."

4.2 Pathogenic variants — spectrum

Classification & mechanism: Pathogenic/likely pathogenic per ACMG/AMP, mechanism loss of function / haploinsufficiency (ClinGen HI score 3).

Variant types. From the 29-patient / 17-unique-variant 2025 cohort (PMID:39837771):

Landmark individual variants (well-documented, good for KB evidence anchors):

Original series composition: Yan et al. reported 10 individuals from 9 unrelated families with 1 missense, 3 nonsense, and 6 frameshift variants; Mattioli et al. reported the index family plus "BRPF1 deletions or point mutations in six additional individuals with a similar phenotype" (PMID:27939639). Yan et al. 2020 added "BRPF1 variants in 12 previously unidentified cases of syndromic intellectual disability" (PMID:32010779).

Total reported cases: Orphanet's epidemiology record cites 79 cases (worldwide, validated, "Cases/families"). PMID:39837771 adds 29 new patients on top of "over 50 previously published cases."

Somatic vs germline: IDDDFP variants are germline (de novo or inherited). BRPF1 also carries somatic mutations in cancer — "the BRPF1 gene is mutated in childhood leukemia and adult medulloblastoma" (PMID:25920810) — and "H3K23 acylation is also impaired by cancer-derived somatic BRPF1 mutations" (PMID:32010779). These are mechanistically related but a distinct disease context; do not conflate them in the disorder entry.

4.3 Population allele frequency and constraint

• gnomAD constraint: BRPF1 is highly LoF-constrained — pLI = 1, LOEUF ≈ 0.21. (Retrieved via web search; the gnomAD GraphQL endpoint requires POST and could not be queried directly. Curators should re-verify the exact pLI/LOEUF/o-e values against gnomAD v4 before citing.)
• DECIPHER Haploinsufficiency Index (%HI): 15.78 (lower = more haploinsufficient), per the ClinGen gene page.
• Pathogenic BRPF1 LoF variants are absent or vanishingly rare in gnomAD — consistent with pLI 1. PMID:32457794 independently excluded their missense variant in 100 ethnically matched controls by Sanger sequencing.
• ClinVar: 577 total submitted BRPF1 variant records; 269 with a pathogenic or likely pathogenic clinical significance assertion (NCBI E-utilities esearch db=clinvar, retrieved 2026-07-31). Note: the P/LP count includes multi-gene CNV records overlapping BRPF1, so it overstates the number of BRPF1-specific sequence-level P/LP variants — do not quote it as "269 pathogenic BRPF1 variants."

4.4 Functional consequences

• Loss of function is the established mechanism. For the index frameshift, PMID:27939639 found: "The mRNA transcript was not significantly reduced in affected fibroblasts and most likely produces a truncated protein (p.Val351Glyfs8). The protein variant shows an aberrant cellular location, loss of certain protein interactions, and decreased histone H3K23 acetylation." — i.e. the truncated protein escapes nonsense-mediated decay* but is functionally null/mislocalized.
• Molecular readouts of pathogenicity: reduced H3K23 acetylation (PMID:27939640; PMID:27939639) and reduced H3K23 propionylation (PMID:32010779). Both are usable as functional assays.
• Mislocalization: nuclear localization of BRPF1 depends on KAT6A, ING5, and MEAF6 (UniProt P55201); truncating variants that remove interaction motifs mislocalize.

4.5 Modifier genes

No validated modifier genes. The strongest candidate is the neighboring SETD5 in contiguous deletions (§4.6) — a contiguous-gene effect rather than a true modifier. Intrafamilial variability with an identical variant (PMID:39837771) implies unidentified genetic and/or stochastic modifiers [gap — explicit open question].

4.6 Chromosomal abnormalities — the 3p25 / 3p25.3 deletion connection

BRPF1 lies within the 3p25 deletion syndrome region, adjacent to SETD5. Mattioli et al. dissected the contributions (PMID:27939639):

"Deletions of the 3p25 region, containing BRPF1 and SETD5, cause a defined ID syndrome where most of the clinical features are attributed to SETD5 deficiency. We compared the clinical symptoms of individuals carrying mutations or small deletions of BRPF1 alone or SETD5 alone with those of individuals with deletions encompassing both BRPF1 and SETD5. We conclude that both genes contribute to the phenotypic severity of 3p25 deletion syndrome but that some specific features, such as ptosis and blepharophimosis, are mostly driven by BRPF1 haploinsufficiency."

This is a strong candidate for a dismech Grouping or comorbidity/contiguous-gene entry — it is a clean worked example of dissecting a contiguous-gene syndrome into per-gene phenotype attribution.

Whole-gene BRPF1 deletions were also recovered from exome CNV analysis in a dystonia cohort (PMID:33611074) — "Within the deletion intervals, BRPF1, CHD8, DJ1, EFTUD2, FGF14, GCH1, PANK2, SGCE, UBE3A, VPS16, WARS2, and WDR45 were determined as the most clinically relevant genes" — indicating BRPF1 CNVs are detectable by exome read-depth analysis (ExomeDepth).

4.7 Epigenetic information

BRPF1 is itself an epigenetic regulator; the disease is an epigenetic lesion (see §6). Two curation-relevant points:

• Histone acylation marks affected: H3K23ac and H3K23pr (propionylation). PMID:32010779 reports the propionylation discovery: "We report that these complexes also catalyze H3K23 propionylation in vitro and in vivo. Immunofluorescence microscopy and ATAC-See revealed the association of this modification with active chromatin."
• DNA methylation episignature: Distinct EpiSign episignatures are established for KAT6A and for the two KAT6B disorders (PMID:37249002). A BRPF1-specific DNA methylation episignature has not been reported [gap]. Given BRPF1's obligate partnership with KAT6A/KAT6B, testing whether BRPF1 patients carry a shared or distinct episignature is a high-value, tractable research question — and would be diagnostically useful for VUS resolution. Do not curate a BRPF1 episignature as if it exists.

5. Environmental Information

• Environmental factors: None. No toxin, radiation, pollution, or occupational exposure is implicated.
• Lifestyle factors: None implicated in causation. (Diet is relevant only as a speculative therapeutic lever — §12.)
• Infectious agents: None. Not applicable.

Recurrent infections were noted in 4/28 (14%) of the 2025 cohort (PMID:39837771), but these are a consequence of the disorder (possibly related to the hematopoietic/immune arm), not an etiologic environmental factor.

6. Mechanism / Pathophysiology

6.1 Causal chain (upstream → downstream)

[MOLECULAR] Heterozygous BRPF1 loss-of-function variant (3p25.3)
↓
[MOLECULAR] BRPF1 haploinsufficiency — reduced scaffold available to assemble
    KAT6A/KAT6B(/KAT7)–BRPF1–ING4/5–MEAF6 tetrameric HAT complexes
↓
[MOLECULAR] Impaired complex assembly, substrate targeting, and enzymatic
    stimulation; mislocalization of truncated protein
↓
[MOLECULAR] Deficient histone H3K23 acetylation AND H3K23 propionylation
    at active chromatin / transcription start sites
↓
[CELLULAR] Deregulated transcription of developmental programs
   (Hox cluster, Robo3, Otx1, Pitx2, Hmx1, Pax6, Runx1/2,
    multipotency genes Slamf1/Mecom/Hoxa9/Hlf/Gfi1/Egr/Gata3)
↓
   ┌───────────────────────┬──────────────────────┬─────────────────────┐
   ↓                       ↓                      ↓                     ↓
[CELLULAR]            [CELLULAR]             [CELLULAR]           [CELLULAR]
Reduced Tbr2+          Reduced dendritic      Impaired GABAergic   Impaired HSC/
intermediate           arborization &         interneuron          progenitor
neuronal progenitors;  spine density;         excitability         self-renewal;
aberrant neurogenesis  altered spine/synapse  (↑ firing threshold, ↑ROS, senescence,
       morphology             ↓ mIPSC amplitude)   apoptosis
   ↓                       ↓                      ↓                     ↓
[TISSUE] Neocortical   [TISSUE] ↓ excitatory  [TISSUE] E/I         [TISSUE] Marrow
abnormality; partial   synaptic transmission  imbalance in         hypoplasia
callosal agenesis      (↓ mEPSC freq & amp)   cortex/hippocampus   (mouse KO)
   ↓                       ↓                      ↓                     ↓
   └───────────────────────┴──────────────────────┘                     ↓
           ↓                                            ↓
[ORGANISM] Intellectual disability, speech/language              [ORGANISM] Anemia,
disorder, hypotonia, seizures, behavioral phenotype               thrombocytopenia
                                                  (rare in humans)

  ‖ parallel developmental arm ‖
[CELLULAR] Deregulated Pitx2/Hmx1/Pax6 in ocular/craniofacial primordia
↓
[TISSUE] Abnormal periocular and craniofacial morphogenesis
↓
[ORGANISM] Ptosis, blepharophimosis, strabismus, optic neuropathy,
   characteristic facial dysmorphism

6.2 Molecular pathways

Primary pathway: MOZ/MORF (KAT6A/KAT6B) histone acetyltransferase complex — lysine acetylation and acylation of histone H3.

BRPF1 is the obligate scaffold. PMID:36077605:

"It functions in the form of a tetrameric complex with a monocytic leukemia zinc finger protein (MOZ or KAT6A), MOZ-related factor (MORF or KAT6B) or HAT bound to ORC1 (HBO1 or KAT7) and two small non-catalytic proteins, the inhibitor of growth 5 (ING5) or the paralog ING4 and MYST/Esa1-associated factor 6 (MEAF6)."

BRPF1's four functions within the complex (PMID:24646517):

"Within these complexes, BRPF1 serves as a scaffold for bridging subunit interaction, stimulating acetyltransferase activity, governing substrate specificity and stimulating gene expression."

Trithorax-group / Hox maintenance pathway. From zebrafish (PMID:18469222):

"brpf1 mutants display anterior transformations of pharyngeal arches due to progressive loss of anterior Hox gene expression. Brpf1 functions in association with the histone acetyltransferase Moz (Myst3), an interaction mediated by the N-terminal domain of Brpf1, and promotes histone acetylation in vivo. Brpf1 recruits Moz to distinct sites of active chromatin and remains at chromosomes during mitosis, mediated by direct histone binding of its bromodomain, which has a preference for acetylated histones, and its PWWP domain, which binds histones independently of their acetylation status. This is the first demonstration of histone binding for PWWP domains."

Emerging: 3D genome / loop-extrusion interplay. A 2025 bioRxiv CRISPR screen implicates the MORF complex including Brpf1 in antagonizing CTCF/cohesin insulation (PMID:40060486): "Among them were the MORF acetyltransferase complex members (Kat6b, Ing5, Brpf1), which could antagonize the transcriptional insulation mediated by CTCF and cohesin complex at developmental genes." [preprint; not peer-reviewed — mark as EMERGING hypothesis if curated]

Suggested GO terms (biological process):

Suggested GO molecular function terms (UniProt P55201, verified): GO:0010698 acetyltransferase activator activity; GO:0140566 histone reader activity; GO:0003677 DNA binding.

Suggested GO cellular component terms (verified): GO:0070776 MOZ/MORF histone acetyltransferase complex (the most specific and informative), GO:0000123 histone acetyltransferase complex, GO:0005634 nucleus.

6.3 Cellular processes

Neurodevelopmental (cortex/hippocampus). Forebrain-conditional KO (PMID:25568313):

"Here, we report that forebrain-specific inactivation of the mouse Brpf1 gene caused early postnatal lethality, neocortical abnormalities, and partial callosal agenesis. With respect to the control, the mutant forebrain contained fewer Tbr2-positive intermediate neuronal progenitors and displayed aberrant neurogenesis. Molecularly, Brpf1 loss led to decreased transcription of multiple genes, such as Robo3 and Otx1, important for neocortical development. Surprisingly, elevated expression of different Hox genes and various other transcription factors, such as Lhx4, Foxa1, Tbx5, and Twist1, was also observed. These results thus identify an important role of Brpf1 in regulating forebrain development and suggest that it acts as both an activator and a silencer of gene expression in vivo."

Synaptic / dendritic (the haploinsufficiency-specific model — most disease-relevant). PMID:31213987:

"Brpf1 heterozygotes showed reduced dendritic complexity in both hippocampal granule cells and cortical pyramidal neurons, accompanied by reduced spine density and altered spine and synapse morphology. An in vitro study of Brpf1 haploinsufficiency also demonstrated decreased frequency and amplitude of miniature EPSCs that may subsequently contribute to abnormal behaviors, including decreased anxiety levels and defective learning and memory."

Excitatory transmission (hippocampus). PMID:34485298:

"We found that mild knockdown of Brpf1 reduced mEPSC frequency of cultured hippocampal neurons, before any significant changes of dendritic morphology showed. We also found that Brpf1 mild knockdown in the hippocampus showed a decreasing trend on the spatial learning and memory ability of mice. Finally, mRNA-Seq analyses showed that genes related to learning, memory, and synaptic transmission (such as C1ql1, Gpr17, Htr1d, Glra1, Cxcl10, and Grin2a) were dysregulated upon Brpf1 knockdown."

Inhibitory transmission (GABAergic interneurons) — E/I imbalance. PMID:33744924:

"Moreover, increased firing threshold, decreased number of evoked action potentials, and a reduced amplitude of miniature inhibitory postsynaptic currents were observed before any significant change of MAP2+ dendritic morphology and in vivo migration ability appeared. Finally, mRNA-Seq analysis revealed that genes related to neurodevelopment and synaptic transmission such as Map2k7 were dysregulated. Our results demonstrated a key role of Brpf1 in inhibitory neurotransmission and related gene expression of GABAergic interneurons."

"Intellectual disability is closely related to impaired GABA neurotransmission. Brpf1 was specifically expressed in medial ganglionic eminence (MGE), a developmental niche of GABAergic interneurons, and patients with BRPF1 mutations showed intellectual disability." — PMID:33744924

Together, PMID:34485298 and PMID:33744924 establish a bidirectional excitation/inhibition disturbance — both excitatory (mEPSC) and inhibitory (mIPSC) synaptic transmission are attenuated. This is a candidate conformance point for epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance in the dismech module set (seizures 14–50%), though note the evidence is MODEL_ORGANISM/IN_VITRO, not human.

Hematopoietic. PMID:27500495:

"Brpf1-deficient pups experienced early lethality due to acute bone marrow failure and aplastic anemia. The mutant bone marrow and fetal liver exhibited severe deficiency in HSCs and hematopoietic progenitors, along with elevated reactive oxygen species, senescence, and apoptosis. BRPF1 deficiency also reduced the expression of multipotency genes, including Slamf1, Mecom, Hoxa9, Hlf, Gfi1, Egr, and Gata3. Furthermore, BRPF1 was required for acetylation of histone H3 at lysine 23, a highly abundant but not well-characterized epigenetic mark."

Cell cycle / proliferation / embryonic vascular development. PMID:25773539:

"Here we present systematic analyses of the mutant animals and demonstrate that the ablation leads to vascular defects in the placenta, yolk sac, and embryo proper, as well as abnormal neural tube closure. At the cellular level, Brpf1 loss inhibits proliferation of embryonic fibroblasts and hematopoietic progenitors. Molecularly, the loss reduces transcription of a ribosomal protein L10 (Rpl10)-like gene and the cell cycle inhibitor p27, and increases expression of the cell-cycle inhibitor p16 and a novel protein homologous to Scp3..."

Skeletal / osteoclast. BRPF bromodomain inhibition "impaired RANKL-induced differentiation of primary murine bone marrow cells and human primary monocytes into bone resorbing osteoclasts by specifically repressing transcriptional programs required for osteoclastogenesis" (PMID:28849908) — relevant to the skeletal features and to BRPF1's known role in "skeletal patterning" (PMID:36077605).

6.4 Protein dysfunction

Loss of a multivalent reader/scaffold, not an enzyme. The truncated protein escapes NMD but shows "aberrant cellular location, loss of certain protein interactions, and decreased histone H3K23 acetylation" (PMID:27939639). No misfolding/aggregation mechanism. Nuclear localization is dependent on KAT6A, ING5, and MEAF6 (UniProt P55201).

Interaction partners (UniProt P55201): KAT6A, KAT6B, KAT7/HBO1, ING5 (and paralog ING4), MEAF6, histones H2AC17 and H4C9.

6.5 Metabolic changes

No primary metabolic defect. One indirect but therapeutically important link: short-chain fatty acid (propionate, butyrate) metabolism intersects with H3K23 acylation, since propionyl-CoA is the donor for propionylation (PMID:32010779). This is a metabolism–epigenome coupling, not a metabolic disease. CHEBI terms: CHEBI:17272 propionate; CHEBI:17968 butyrate; CHEBI:39549 valproic acid; CHEBI:45716 vorinostat.

6.6 Immune system involvement

Not an immunologic disease. Two peripheral observations: recurrent infections in 4/28 (14%) (PMID:39837771), and the hematopoietic arm (bone marrow failure in mouse KO, PMID:27500495; anemia + thrombocytopenia in a human family, PMID:37190896). Whether human BRPF1 haploinsufficiency causes clinically meaningful immune dysfunction is unresolved [gap].

6.7 Tissue damage mechanisms

In the hematopoietic compartment, mouse KO shows elevated reactive oxygen species, senescence, and apoptosis (PMID:27500495). No oxidative-stress, ischemic, fibrotic, or necrotic mechanism is described in the CNS. The CNS phenotype is developmental (hypoplastic/miswired) rather than degenerative.

6.8 Biochemical abnormalities

The core biochemical lesion is a quantitative deficit in two histone acyl marks: - H3K23 acetylation ↓ (PMID:27939640, PMID:27939639, PMID:27500495) - H3K23 propionylation ↓ (PMID:32010779)

There is no measurable serum/urine biochemical abnormality; these are chromatin-level assays on patient fibroblasts/cells. No enzyme deficiency, receptor dysfunction, or ion-channel defect in the classical sense — though the functional consequence in neurons is altered excitability (PMID:33744924).

6.9 Molecular profiling

• Transcriptomics: mRNA-Seq in Brpf1-knockdown hippocampal neurons — dysregulation of C1ql1, Gpr17, Htr1d, Glra1, Cxcl10, Grin2a (PMID:34485298); in MGE-derived GABAergic interneurons — Map2k7 and other neurodevelopment/synaptic genes (PMID:33744924); in forebrain KO — ↓ Robo3, Otx1; ↑ Hox genes, Lhx4, Foxa1, Tbx5, Twist1 (PMID:25568313); in fetal HSC — ↓ Slamf1, Mecom, Hoxa9, Hlf, Gfi1, Egr, Gata3 (PMID:27500495). Ocular-relevant: "Loss of BRPF1 has been shown to affect the transcriptional regulation of several key transcription factors, including Pitx2, Hmx1 and Pax6, which have been implicated in a wide range of ocular developmental abnormalities." (PMID:39837771).
• Chromatin accessibility / imaging: ATAC-See and immunofluorescence localized H3K23 propionylation to active chromatin (PMID:32010779).
• Proteomics, metabolomics, lipidomics: No disease-specific studies [gap].
• Single-cell / spatial transcriptomics: No BRPF1-specific studies [gap]. The forebrain KO Tbr2+ progenitor finding (PMID:25568313) is a natural target for scRNA-seq.
• Functional genomics screens: the CRISPR screen in PMID:40060486 (preprint) recovered Brpf1 as a modulator of loop-extrusion-dependent gene regulation.
• Structural biology: co-crystal structures of the BRPF1 bromodomain exist from chemical-probe programs (PMID:26061247 — "structure guided development … through the iterative use of X-ray cocrystal structures"). AlphaFold model available for P55201.

7. Anatomical Structures Affected

7.1 Organ level

Primary: | Structure | UBERON | Basis | |---|---|---| | Brain | UBERON:0000955 | ID, DD, MRI findings | | Cerebral cortex / neocortex | UBERON:0000956 / UBERON:0001950 | Reduced dendritic complexity in cortical pyramidal neurons (PMID:31213987); neocortical abnormalities (PMID:25568313) | | Hippocampal formation | UBERON:0002421 | Reduced granule-cell dendritic complexity, ↓mEPSC, spatial memory (PMID:31213987; PMID:34485298) | | Corpus callosum | UBERON:0002336 | Agenesis 2/17 MRI (PMID:39837771); partial callosal agenesis in mouse (PMID:25568313) | | Eye / eyelid | UBERON:0000970 / UBERON:0001711 | Ptosis, blepharophimosis — BRPF1-specific (PMID:27939639) | | Optic nerve | UBERON:0000941 | Subclinical optic neuropathy (PMID:38590032) | | Face / craniofacial skeleton | UBERON:0000033 (head) / UBERON:0001434 | Characteristic dysmorphism |

Secondary / variable: | Structure | UBERON | Basis | |---|---|---| | Bone marrow | UBERON:0002371 | Anemia/thrombocytopenia (PMID:37190896); marrow failure in mouse KO (PMID:27500495) | | Cervical vertebral column | UBERON:0000959 | C2/C3 fusion 3/10 (HPOA); atlanto-axial malformation (PMID:35243762) | | Spinal cord | UBERON:0002240 | "Central nervous system and spinal abnormalities are also seen in some individuals" (PMID:27939640) | | Heart | UBERON:0000948 | Cardiac anomalies in a subset (PMID:32010779); 1/25 (PMID:39837771) | | Esophagus / upper GI | UBERON:0001043 | GERD 31% | | Larynx | UBERON:0001737 | Laryngomalacia 7% | | Skeletal muscle | UBERON:0001134 | Hypotonia, weakness | | Skin / hair follicle | UBERON:0002097 / UBERON:0002073 | Hypertrichosis, hair abnormalities (novel, PMID:39837771) | | Testis / gonad | UBERON:0000473 | Cryptorchidism 19% |

Body systems: nervous (primary), visual/ophthalmic (primary), musculoskeletal, craniofacial, hematopoietic, gastrointestinal, integumentary, genitourinary.

7.2 Tissue and cell level

Curator caution: every CL/UBERON/GO ID above must be re-verified with just validate-terms — some (notably the PV-interneuron term) are suggestions requiring OAK confirmation.

7.3 Subcellular level

BRPF1 "localizes to transcription start sites" (UniProt P55201).

7.4 Localization and lateralization

• Ptosis/blepharophimosis: typically bilateral, may be asymmetric.
• Optic neuropathy: reported bilateral — "such an exam also detected bilateral subclinical optic neuropathy in this case" (PMID:38590032).
• Facial asymmetry: 3/28 (11%) (PMID:39837771).
• Brain findings: midline (corpus callosum) and diffuse (white matter volume), not lateralized.
• Strabismus: unilateral or bilateral, variable.

8. Temporal Development

8.1 Onset

• Congenital — HPOA: HP:0003577 Congenital onset (10/10); HP:0003623 Neonatal onset (4/4).
• Prenatal: intrauterine growth restriction 2/20 (HP:0001511). Mouse Brpf1 is required from ~E9.5 (PMID:24646517), so human haploinsufficiency acts throughout embryogenesis.
• Neonatal/infantile: congenital ptosis, hypotonia (9/15 infant hypotonia), feeding impairment (8/15) (PMID:38346666; PMID:27939640).
• Infancy–early childhood: motor and speech delay become apparent; delayed walking.
• School age: language disorder (including written-language domain), ADHD, learning difficulty predominate.
• Onset pattern: chronic, insidious, developmental — not acute or episodic.

8.2 Progression

• Stages: No formal staging system exists. Practical natural-history phases: (i) neonatal/infantile — hypotonia, feeding, congenital ptosis; (ii) toddler/preschool — motor and speech delay; (iii) school age — language disorder, ID, behavioral phenotype; (iv) adolescence/adulthood — stable ID, largely resolved gross-motor delay, ongoing communication needs.
• Progression rate: Non-progressive. No neurodegeneration reported in any human series.
• Course pattern: Static/stable with developmental improvement. PMID:38346666 explicitly documents improvement: motor delays "often resolved in later childhood."
• Duration: Chronic, lifelong.
• Seizures, when present (14–50%), are episodic on a static substrate.

8.3 Patterns

• Remission: Not applicable to the core neurodevelopmental phenotype. Gross-motor delay commonly resolves; ptosis is surgically correctable; seizures may be pharmacologically controlled.
• Critical periods: (i) embryonic — the window in which forebrain neurogenesis, callosal formation, and ocular/craniofacial morphogenesis are set (irreversible by the time of diagnosis); (ii) infancy–early childhood — the intervention window for speech/language therapy, feeding support, and amblyopia prevention (ptosis surgery before visual-axis deprivation causes irreversible amblyopia). The speech-therapy window is the highest-yield intervention target given the near-universal speech/language phenotype (PMID:38346666).

9. Inheritance and Population

9.1 Epidemiology

• Prevalence: Orphanet records a worldwide point prevalence class of "<1 / 1,000,000" (validated) for ORPHA:698090 — i.e. < 0.1 per 100,000. Orphanet's prevalence_class maps to the dismech PrevalenceClassEnum value BELOW_1_IN_1000000.
• Reported case count: Orphanet's second epidemiology record gives 79 cases (worldwide, "Cases/families", validated). This is the more defensible figure to curate as measure_type: CASES_IN_LITERATURE.
• Incidence: Not established [gap]. No birth-prevalence or incidence estimate exists.
• Likely underdiagnosis: PMID:35243762 argues "Later, another 20 patients were also described by distinct reports, suggesting IDDDFP could be a more frequent cause of intellectual disability as it was thought before." Given the mild phenotype, high FSIQ, and preserved adaptive behavior, ascertainment is likely incomplete.

Suggested dismech Prevalence record:

prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  notes: Orphanet worldwide point-prevalence class <1 / 1 000 000 (validated).
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  rate_per_100000: null
  notes: >-
    Orphanet records 79 cases worldwide (validated). Colson et al. 2025 add
    29 new patients from 20 families to "over 50 previously published cases."

9.2 Genetic etiology parameters

9.3 Population demographics

• Affected populations: No ethnic predilection. Reported in European, Israeli/Jewish (mixed descent), Turkish, Saudi Arabian, Latin American, and North American families.
• Geographic distribution: Worldwide; no endemic focus. No geographically clustered variant.
• Sex ratio: Male predominance in reported series (10/15 male in PMID:38346666) — almost certainly ascertainment bias, not a true sex effect; the gene is autosomal. Curate as unknown/1:1 rather than asserting a skew.
• Age distribution: Pediatric-diagnosed, lifelong. Median age 7y4m in the deep-phenotyping cohort (PMID:38346666). Adults are described chiefly as transmitting parents.

10. Diagnostics

10.1 Genetic testing — the diagnostic mainstay

There is no biochemical or imaging biomarker; diagnosis is molecular.

Recommended approach: ES (trio, with CNV calling) as first-tier for the ID/DD + ptosis phenotype; CMA if ES-CNV not performed; Sanger cascade testing of parents and at-risk relatives — essential, because mildly affected transmitting parents are common and change recurrence risk from ~1% to 50%.

10.2 Omics-based diagnostics

• Functional H3K23 acetylation/propionylation assay on patient cells — used as research-grade evidence of pathogenicity for VUS (PMID:27939640; PMID:32010779). Not a clinically validated assay [gap: no CLIA/accredited version].
• DNA methylation episignature (EpiSign) — not available for BRPF1 (established for KAT6A and KAT6B, PMID:37249002). This is the single most useful missing diagnostic tool for BRPF1 VUS resolution.
• RNA-seq / proteomics / metabolomics / liquid biopsy — no diagnostic role.

10.3 Clinical and imaging tests

LOINC coding: no BRPF1-specific LOINC analyte. Use generic genetic-test LOINC codes and standard CBC codes for the hematologic monitoring.

10.4 Clinical criteria and differential diagnosis

No consensus clinical diagnostic criteria exist [gap]. Diagnosis = compatible phenotype + confirmed heterozygous pathogenic BRPF1 variant.

Differential diagnosis:

10.5 Screening

• Newborn screening: Not applicable and not recommended (no treatable metabolic defect).
• Carrier screening: Not applicable (dominant).
• Cascade screening: Strongly indicated — targeted Sanger testing of the proband's parents and at-risk relatives. Multiplex families with mildly affected transmitting parents are well documented (PMID:27939639; PMID:31020800; PMID:37190896; PMID:39837771). Parental testing is what distinguishes ~1% from 50% recurrence risk.

11. Outcome / Prognosis

11.1 Survival and mortality

• Life expectancy: apparently normal. No abstract reports reduced survival, premature mortality, or disease-specific deaths in humans. Affected adults reproduce and transmit the variant (PMID:27939639 — 5 affected members; PMID:31020800 — affected mother and three sons).
• Important contrast — do not extrapolate from mouse: homozygous Brpf1 null is embryonic lethal at E9.5 (PMID:24646517; PMID:25773539); conditional hematopoietic deletion causes "early lethality due to acute bone marrow failure and aplastic anemia" (PMID:27500495); forebrain-specific deletion causes "early postnatal lethality" (PMID:25568313). These are homozygous/conditional-null phenotypes with no human counterpart — human disease is heterozygous. Curate as a HUMAN_MODEL_MISMATCH discussion, not as a human prognosis claim.
• Mortality rate / 5-yr and 10-yr survival: Not applicable; no excess mortality documented [no data].

11.2 Morbidity and function

• Dominant disability: communication impairment. Language disorder in 11/12 assessed, speech disorder in 7/9, childhood apraxia of speech in 3/9 (PMID:38346666).
• Cognitive outcome: favorable relative to peer chromatinopathies. Mild-to-moderate ID predominates (6 mild / 10 moderate of 16 with ID); no severe/profound ID in the 2025 cohort; FSIQ ≥70 in all four formally tested in the deep-phenotyping cohort (PMID:38346666; PMID:39837771).
• Adaptive functioning: a relative strength — "Adaptive behavior and cognition were strengths when compared to other monogenic neurodevelopmental chromatin-related disorders" (PMID:38346666).
• Motor outcome: favorable — delays "often resolved in later childhood" (PMID:38346666).
• Visual outcome: the main organ-specific morbidity risk — vision impairment in 13/15, amblyopia in 3/29, and undetected subclinical optic neuropathy (PMID:38346666; PMID:39837771; PMID:38590032).
• QoL instruments: none applied to this population [gap].

11.3 Complications

Amblyopia from uncorrected ptosis; refractive error; optic neuropathy; seizures; GERD and constipation; feeding difficulty and failure to thrive in infancy; recurrent infections (14%); anemia/thrombocytopenia (8%); obesity (14%); cervical spine instability (atlanto-axial malformation / C2-C3 fusion) with anesthetic and injury implications; educational underachievement and social-communication limitation.

11.4 Recovery potential

The neurodevelopmental substrate is fixed (developmental, not degenerative), but functional trajectory improves with intervention — motor delays resolve, and speech/language and adaptive skills respond to therapy. Ptosis is surgically correctable. There is no disease-modifying therapy and no evidence that any intervention alters the underlying chromatin defect in humans.

11.5 Prognostic factors and biomarkers

No validated prognostic factors or biomarkers. Explicitly:

"Our results, in agreement with other studies, do not show a clear genotype–phenotype correla[tion]" — PMID:39837771 (quote truncated at source by the extraction tool; curators must re-read the full sentence from PMC11973018 before quoting)

Variant type (truncating vs missense vs whole-gene deletion) and variant position do not predict severity. Intrafamilial variability with an identical variant (PMID:39837771) is direct evidence that genotype alone is insufficiently prognostic. Favorable indicators are clinical, not molecular: preserved adaptive behavior, FSIQ ≥70, and resolving motor delay.

12. Treatment

There is no disease-modifying or curative therapy. Management is entirely supportive, multidisciplinary, and symptom-directed. No clinical trial has ever been registered for BRPF1-related disorder (no NCT identifiers found).

12.1 Supportive and rehabilitative care — the standard of care

12.2 Ophthalmologic management — the disorder-specific priority

12.3 Pharmacotherapy

Symptomatic only: - Antiseizure medication for the 14–50% with seizures — no BRPF1-specific agent preference established [gap]. NCIT:C15986 Pharmacotherapy; therapeutic_agent per drug chosen. - ADHD stimulants / non-stimulants — standard NDD practice; no BRPF1-specific evidence. - Anti-reflux therapy for GERD (31%). - Pharmacogenomics: No BRPF1-specific PGx. PharmGKB has no BRPF1 clinical annotation. Note that if valproate were ever used as an antiseizure drug, there is an interesting mechanistic coincidence with §12.4 — but this is not a validated indication.

12.4 Experimental / mechanism-based therapeutic leads

This is the most scientifically interesting and most easily over-claimed section. Nothing below has been tested in a human with BRPF1-related disorder.

The key finding (PMID:32010779):

"Valproate, vorinostat, propionate and butyrate promote H3K23 acylation. These results reveal the dual functionality of BRPF1-KAT6 complexes, shed light on mechanisms underlying related developmental disorders and various cancers, and suggest mutation-based therapy for medical conditions with deficient histone acylation."

Candidate agents and their CHEBI/NCIT anchors:

Framing guardrail for curation: the mechanistic logic is restore the deficient H3K23 acyl mark. But (i) the data are entirely in vitro/mouse; (ii) the developmental window for the CNS/craniofacial phenotype has closed by the time of diagnosis; (iii) valproate is a known teratogen and an HDAC inhibitor is a blunt, genome-wide instrument. Curate as EMERGING / mechanistic_hypotheses, never as a treatment.

Bromodomain chemical probes — a research tool, and directionally opposite to therapy. Selective BRPF bromodomain inhibitors exist: IACS-9571 (dual TRIM24/BRPF1, ITC Kd = 14 nM for BRPF1, PMID:26061247) and PFI-4 / OF-1 / NI-57 (PMID:28849908). These inhibit BRPF1 and would be expected to worsen a haploinsufficiency phenotype; their therapeutic interest is in cancer and osteolytic bone disease — "the excellent druggability of these bromodomains may lead to new treatment strategies for patients suffering from bone loss or osteolytic malignant bone lesions" (PMID:28849908). Do not curate these as candidate treatments for IDDDFP.

12.5 Advanced therapeutics

• Gene therapy / gene editing: None. No program exists. Conceptually challenging: the target is a large (1,214 aa, ~3.6 kb CDS) nuclear scaffold requiring precise dosage in the developing brain — dosage-sensitive genes are poor AAV overexpression targets.
• RNA-based therapies (ASO, siRNA, mRNA): None. Note that for a haploinsufficiency disorder, the relevant ASO paradigm would be upregulation (e.g. TANGO/splice-modulation to boost expression from the intact allele), not the RNase H knockdown or exon-skipping paradigms in the dismech antisense_oligonucleotide_therapy module. No such program exists for BRPF1 [gap].
• Cell therapy, immunotherapy, targeted therapy: Not applicable.

12.6 Treatment strategy

No published treatment algorithm, guideline, or care pathway exists for BRPF1-related disorder [gap]. Practical management follows generic chromatinopathy/NDD care plus the two disorder-specific additions the literature does support: (1) structured, apraxia-aware speech-language intervention (PMID:38346666) and (2) regular ophthalmological surveillance including OCT (PMID:39837771; PMID:38590032).

13. Prevention

• Primary prevention: Not possible for de novo cases. For families with a known variant, options are preimplantation genetic testing (PGT-M) and prenatal diagnosis (CVS/amniocentesis) — standard for a known AD variant with 50% recurrence risk. Orphanet: transmission is autosomal dominant; "genetic counseling should be offered to affected individuals informing them that there is a 50% risk of having an affected child at each pregnancy."
• Secondary prevention (early detection): The highest-value activity. Early molecular diagnosis via trio ES enables (i) early speech/language therapy in the critical window, (ii) ophthalmological surveillance before amblyopia becomes fixed, and (iii) cascade family testing.
• Tertiary prevention (complication prevention):
• Ptosis repair before deprivation amblyopia — the clearest preventable harm.
• OCT surveillance for otherwise-silent optic neuropathy (PMID:38590032).
• Cervical spine assessment before anesthesia or contact sports (C2/C3 fusion, atlanto-axial malformation).
• CBC monitoring where hematologic abnormality is suspected (PMID:37190896).
• Seizure control; reflux and constipation management; weight monitoring (obesity 14%).
• Immunization: No disorder-specific vaccine strategy. Routine childhood immunization per national schedule; the 14% recurrent-infection rate warrants normal-to-diligent vaccine adherence.
• Population screening / newborn screening: Not indicated — no treatable metabolic defect, no validated screening test, prevalence <1/1,000,000.
• Risk stratification: Not applicable at the population level; within families, cascade genetic testing is the stratifier.
• Behavioral / environmental / public health interventions: Not applicable — no environmental contribution to etiology.
• Prophylaxis: No prophylactic medication.
• Genetic counseling: Central. Counsel on (i) 50% recurrence for an affected parent; (ii) marked variable expressivity, including the possibility of a much milder or even cognitively normal outcome (PMID:35243762; PMID:39837771) — a parent transmitting the variant cannot be told the child will be similarly affected; (iii) the need to test apparently unaffected parents, since mild transmitting parents are common; (iv) residual germline-mosaicism risk for apparently de novo cases. NCIT:C15240 Genetic Counseling.

14. Other Species / Natural Disease

14.1 Taxonomy and orthologs

Verify MGI:1926033 and the mouse chromosome/coordinates directly at informatics.jax.org before curating — the identifier came from a web search snippet, not a fetched MGI record.

14.2 Evolutionary conservation

Strong. PMID:40593218: "The evolutionary conservation of these complexes in Drosophila melanogaster and Caenorhabditis elegans underscores their fundamental biological significance." PMID:36077605 notes the four core subunits "play crucial roles in different biological processes across diverse species, such as embryonic development, forebrain development, skeletal patterning and hematopoiesis." Both patient missense variants in the 2025 cohort — p.(Cys23Arg) and p.(Arg548Trp) — "affect conserved residue[s]" (PMID:39837771).

14.3 Natural disease in other species

No naturally occurring BRPF1 disease is recorded in companion animals, livestock, or wildlife. OMIA contains no BRPF1 entry [gap]. All non-human BRPF1 phenotypes are engineered, not natural. No breed-specific (VBO) association exists.

14.4 Comparative pathology

The mouse and zebrafish phenotypes are informative but more severe than human disease, because they are homozygous/conditional nulls rather than heterozygous LoF. Key comparative points: - Mouse homozygous null: embryonic lethal ~E9.5; vascular defects in placenta, yolk sac, embryo proper; abnormal neural tube closure (PMID:24646517; PMID:25773539). No human counterpart. - Zebrafish brpf1 mutant: "anterior transformations of pharyngeal arches due to progressive loss of anterior Hox gene expression" (PMID:18469222) — a homeotic craniofacial phenotype. This is mechanistically suggestive for the human craniofacial dysmorphism but the human phenotype is not homeotic. - Mouse heterozygote: the closest model to human disease — reduced dendritic arborization, spine deficits, learning/memory impairment (PMID:31213987).

14.5 Transmission

Not applicable. Not infectious; no zoonotic potential; no cross-species susceptibility.

15. Model Organisms

15.1 Mouse — the principal model

15.2 Zebrafish

brpf1 mutants: "anterior transformations of pharyngeal arches due to progressive loss of anterior Hox gene expression"; Brpf1 recruits Moz to active chromatin and remains chromosome-bound through mitosis; the PWWP domain "is absolutely essential for Brpf1 function in vivo" (PMID:18469222). Establishes Brpf1 as a Trithorax-group member and provides the first demonstration of histone binding by a PWWP domain.

15.3 Other systems

• In vitro / cellular: patient-derived skin fibroblasts (used for transcript/protein/H3K23ac assays — PMID:27939639); mouse embryonic fibroblasts (PMID:25773539); primary cultured hippocampal neurons (PMID:34485298); primary murine bone marrow cells and human primary monocytes for osteoclast differentiation (PMID:28849908); mouse ES cells (PMID:40060486).
• iPSC / organoid models: none reported [gap]. This is a conspicuous, high-value missing model given the human-specific cortical biology at issue.
• Induced (non-genetic) models: chemical-probe inhibition of the BRPF bromodomain (IACS-9571, PFI-4, OF-1, NI-57) provides an acute pharmacological loss-of-function tool (PMID:26061247; PMID:28849908) — though it targets only the bromodomain, not the whole scaffold.

15.4 Phenotype recapitulation and limitations

Recapitulated in the heterozygous mouse: learning/memory deficits, reduced dendritic arborization and spine density, reduced excitatory synaptic transmission, altered anxiety behavior (PMID:31213987) — a good mechanistic match to human ID.

Recapitulated in conditional/homozygous models but NOT matching human severity: callosal agenesis (partial in mouse KO vs 12% in humans), bone marrow failure (lethal in mouse vs mild anemia/thrombocytopenia in 8% of humans), embryonic lethality (mouse only).

Not recapitulated / not modeled: - Ptosis and blepharophimosis — the single most characteristic human feature. No abstract reports a murine eyelid phenotype. [Major gap.] - Speech and language disorder / childhood apraxia of speech — the most functionally significant human phenotype, and intrinsically unmodellable in mouse. - Human-specific cortical biology (outer radial glia/OSVZ) absent from rodent models. - The zebrafish homeotic pharyngeal-arch transformation has no human correlate.

Suggested dismech curation: record a discussions entry with kind: HUMAN_MODEL_MISMATCH (not KNOWLEDGE_GAP) for at least two items: (1) the mouse models are homozygous/conditional nulls producing lethality, while human disease is heterozygous and compatible with normal lifespan; and (2) no model reproduces ptosis/blepharophimosis, the disorder's defining feature — so the ocular/periocular developmental mechanism (the Pitx2/Hmx1/Pax6 hypothesis from PMID:39837771) remains functionally unvalidated. Per CLAUDE.md, HUMAN_MODEL_MISMATCH is the right kind here because evidence exists in models but its translational validity is the open question.

15.5 Resources

MGI (mouse; MGI:1926033 — verify), IMPC/EUCOMM/KOMP (Brpf1^tm1a(EUCOMM)Wtsi, MGI:4433631), IMSR, ZFIN (zebrafish brpf1), Alliance of Genome Resources.

Appendix A — Consolidated PMID reference list

Clinical — foundational - PMID:27939640 — Yan K, Rousseau J, Littlejohn RO, et al. Mutations in the Chromatin Regulator Gene BRPF1 Cause Syndromic Intellectual Disability and Deficient Histone Acetylation. Am J Hum Genet. 2017. [Disease-defining paper #1 — 10 individuals] - PMID:27939639 — Mattioli F, Schaefer E, Magee A, et al. Mutations in Histone Acetylase Modifier BRPF1 Cause an Autosomal-Dominant Form of Intellectual Disability with Associated Ptosis. Am J Hum Genet. 2017. [Disease-defining paper #2 — 3p25/SETD5 dissection]

Clinical — cohorts and deep phenotyping - PMID:39837771 — Colson C, et al. The Phenotypic and Genotypic Spectrum of BRPF1-Related Disorder: 29 New Patients and Literature Review. Clin Genet. 2025. [Largest cohort; primary frequency source; PMC11973018] - PMID:38346666 — Beyond 'speech delay': Expanding the phenotype of BRPF1-related disorder. Eur J Med Genet. 2024. [Speech/language deep phenotyping, n=15] - PMID:38590032 — Broadening the ocular phenotypic spectrum of ultra-rare BRPF1 variants: report of two cases. Ophthalmic Genet. 2024. [Subclinical optic neuropathy; Chiari I] - PMID:31020800 — Pode-Shakked N, et al. BRPF1-associated intellectual disability, ptosis, and facial dysmorphism in a multiplex family. Mol Genet Genomic Med. 2019. - PMID:37190896 — Kose CC, et al. Anemia and thrombocytopenia due to a novel BRPF1 variant… Am J Med Genet A. 2023. [Hematologic expansion] - PMID:35243762 — BRPF1-associated syndrome: A patient with congenital ptosis, neurological findings, and normal intellectual development. Am J Med Genet A. 2022. [Mild end of spectrum] - PMID:32457794 — Novel Missense Variant in Heterozygous State in the BRPF1 Gene… Front Genet. 2020. - PMID:41137536 — Non-RASopathy Genetic Syndromes Identified as the Molecular Cause of Disease in Patients Previously Diagnosed With Noonan Syndrome. Am J Med Genet A. 2026. [Differential diagnosis] - PMID:33611074 — Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. Parkinsonism Relat Disord. 2021. [BRPF1 CNV detection]

Mechanism — molecular - PMID:32010779 — Yan K, et al. Deficient histone H3 propionylation by BRPF1-KAT6 complexes in neurodevelopmental disorders and cancer. Sci Adv. 2020. [H3K23pr; 12 new cases; therapeutic leads] - PMID:36077605 — BRPF1-KAT6A/KAT6B Complex: Molecular Structure, Biological Function and Human Disease. Cancers. 2022. [Review] - PMID:40593219 — Bromodomain and PHD Finger-Containing Protein 1: From Functions to a Developmental Disorder, Cancer, and Therapeutics. Results Probl Cell Differ. 2025. [Most recent dedicated review] - PMID:40593218 — Lysine Acetyltransferase 6 Complexes in Neurodevelopmental Disorders and Different Types of Cancer. Results Probl Cell Differ. 2025. - PMID:25920810 — Yang XJ. MOZ and MORF acetyltransferases… Biochim Biophys Acta. 2015.

Mechanism — model organism - PMID:31213987 — Brpf1 Haploinsufficiency Impairs Dendritic Arborization and Spine Formation, Leading to Cognitive Deficits. Front Cell Neurosci. 2019. [Best disease-matched model] - PMID:25568313 — Deficiency of the chromatin regulator BRPF1 causes abnormal brain development. J Biol Chem. 2015. - PMID:34485298 — Deficiency of Intellectual Disability-Related Gene Brpf1 Attenuated Hippocampal Excitatory Synaptic Transmission… Front Cell Dev Biol. 2021. - PMID:33744924 — Deficiency of intellectual disability-related gene Brpf1 reduced inhibitory neurotransmission in MGE-derived GABAergic interneurons. G3. 2021. - PMID:27500495 — BRPF1 is essential for development of fetal hematopoietic stem cells. J Clin Invest. 2016. - PMID:25773539 — The chromatin regulator Brpf1 regulates embryo development and cell proliferation. J Biol Chem. 2015. - PMID:24646517 — Expression atlas of the multivalent epigenetic regulator Brpf1… Epigenetics. 2014. - PMID:18469222 — Laue K, et al. The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. Development. 2008. [Zebrafish; PWWP histone binding] - PMID:21753189 — The Hbo1-Brd1/Brpf2 complex … required for fetal liver erythropoiesis. Blood. 2011. [Paralog — do not conflate with BRPF1] - PMID:40060486 — Context-Dependent and Gene-Specific Role of Chromatin Architecture… bioRxiv 2025. [Preprint — not peer reviewed]

Chemical biology / therapeutics - PMID:26061247 — Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016. - PMID:28849908 — Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation. ACS Chem Biol. 2017.

Adjacent / comparison - PMID:37249002 — DNA methylation episignatures are sensitive and specific biomarkers for detection of patients with KAT6A/KAT6B variants. [No BRPF1 episignature — cited as a gap]

Non-literature structured sources usable as dismech evidence references: - ORPHA:698090 — Orphanet (definition, prevalence class <1/1,000,000, 79 cases, disorder type) - CGDS:HGNC_14255 — ClinGen Dosage Sensitivity (HI score 3, TS score 0, curated 2023-08-23) - ClinGen Gene-Disease Validity (CGGV: — retrieve the specific assertion ID via just clingen-list | grep BRPF1)

Appendix B — Curation notes and explicitly flagged gaps

Things to verify before committing (per CLAUDE.md SOP): 1. Run just fetch-reference PMID:X for all ~28 PMIDs above; then just validate-references — several quotes above came through a summarizing fetch layer and, while transcribed verbatim on request, must be substring-checked against the real cached abstracts. 2. The Colson 2025 genotype-phenotype sentence was truncated mid-word by the extraction tool. Re-read it from PMC11973018 before quoting. 3. gnomAD pLI=1 / LOEUF=0.21 came from a search snippet, not from gnomAD directly. Re-verify against gnomAD v4. 4. MGI:1926033 came from a search snippet. Verify at informatics.jax.org. 5. Verify every CL, UBERON, GO, CHEBI, and NCIT ID with just validate-terms. The PV-interneuron CL term and the eyeglasses NCIT term are the least certain. 6. The ClinVar "269 P/LP" count includes multi-gene CNVs — do not quote it as BRPF1-specific sequence variants.

Substantive knowledge gaps worth recording as discussions entries: - No BRPF1 DNA-methylation episignature despite established episignatures for its obligate partners KAT6A/KAT6B (PMID:37249002) — the single highest-value diagnostic gap. - No iPSC or cerebral-organoid model — no human-cell model of the neurodevelopmental phenotype. - No animal model of ptosis/blepharophimosis — the defining human feature is mechanistically unvalidated; the Pitx2/Hmx1/Pax6 route (PMID:39837771) is inference, not demonstration. - No quantitative penetrance estimate, and no explanation for the intrafamilial variability seen with identical variants — implies unidentified modifiers. - No natural history study, no QoL data, no treatment guideline, no clinical trial. - Whether human BRPF1 haploinsufficiency causes clinically meaningful hematologic or immune disease is unresolved (8% hematologic abnormality vs lethal marrow failure in mouse KO). - The mouse-vs-human severity mismatch (homozygous-null lethality vs normal human lifespan) should be an explicit HUMAN_MODEL_MISMATCH, not a KNOWLEDGE_GAP.

Candidate dismech module conformance points: - epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance — supported by paired excitatory (PMID:34485298) and inhibitory (PMID:33744924) transmission deficits, but the evidence is MODEL_ORGANISM/IN_VITRO only; seizures occur in a minority. Curate the conformance with that caveat, or not at all. - A potential new chromatinopathy / KAT6-BRPF1 complex module or Grouping uniting BRPF1, KAT6A, and KAT6B disorders — they share an obligate protein complex, a common molecular readout (H3K23 acylation), and overlapping phenotypes, which is exactly the SHARED_MECHANISM + SHARED_PATHWAY grouping basis. - A 3p25 contiguous deletion entry or grouping capturing the BRPF1/SETD5 per-gene phenotype attribution (PMID:27939639) — an unusually clean worked example.

Sources: - OMIM 617333 — IDDDFP - OMIM 602410 — BRPF1 - Orphanet ORPHA:698090 - Orphadata API — cross-referencing and epidemiology, ORPHA:698090 - ClinGen — BRPF1 dosage sensitivity (HGNC:14255) - ClinGen — BRPF1 gene page - MedGen 934584 - HPO API — annotations for OMIM:617333 - OLS4 — MONDO:0015022 - UniProt P55201 — Peregrin/BRPF1 - HGNC:14255 — BRPF1 - PubMed — BRPF1 (all abstracts cited above retrieved via NCBI E-utilities) - PMC11973018 — Colson et al. 2025, Clinical Genetics - ScienceDirect — Beyond 'speech delay': Expanding the phenotype of BRPF1-related disorder - Science Advances — Deficient histone H3 propionylation by BRPF1-KAT6 complexes - MGI — Brpf1 (MGI:1926033) - MGI — Brpf1^tm1a(EUCOMM)Wtsi (MGI:4433631) - PMC9454415 — BRPF1-KAT6A/KAT6B Complex review - PubMed 37249002 — KAT6A/KAT6B episignatures